Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

TITAN BIO-TECH LTD.

NSE : NABSE : 524717ISIN CODE : INE150C01011Industry : ChemicalsHouse : Private

BSE1036.1042.55 (+4.28 %)

PREV CLOSE ( ) 993.55

OPEN PRICE ( ) 1025.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 13205

TODAY'S LOW / HIGH ( )1000.00 1043.00

52 WK LOW / HIGH ( ) 373.651419

NSE

This Company is not listed in NSE

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 18-02 1992

Management Info

Rohit Jain - Chairman Suresh Chand Singla - Managing Director

Registered Office

Address A - 902 A,R I I C O Industrial Area,Phase 3,
Bhiwadi,
Rajasthan-301019

Phone 011-27355742 / 27674615

Email hrd@titanbiotechltd.com / accounts@titanbiotechltd.com / purchase@titanbiotechltd.com

Website www.titanbiotechltd.com / www.tmmedia.in

Registrars Details

Beetal Financial & Computer Services (P) Ltd

Beetal House , 99 Mandangir,3rd Floor, Behind Local Shopping Centre,Near Dada Harsukhdas Mandir,New Delhi

Listing : BSE

NEWS

29Nov Titan Biotec informs about outcome of
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

29Nov Titan Biotech submits intimation of su
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

29Nov Titan Biotech informs about notice of
Pursuant to Regulation 30 of the Securities and Exchange Board of India..

25Nov Titan Biotech informs about board meet
Pursuant to Regulation 29 read with regulation 33 of the SEBI (Listing O..

25Nov Titan Biotech informs about closure of
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015..

Financials

Rs. in Millions

	QTR Sep 25	ANNUAL 25
Net Profit	68.62	182.7
Gross Profit	92.18	243.66
Operating Profit	106.52	293.38
Net Sales	543.55	1564.51

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Polson (BSE) 11499.65 (1.48%)	M.Cap ( in Cr)138.00
Neogen Chemicals (BSE) 1098.35 (11.34%)	M.Cap ( in Cr)2897.63
Navin Fluorine Intl (BSE) 6043.95 (1.62%)	M.Cap ( in Cr)30968.67
Elantas Beck India (BSE) 9451.30 (0.75%)	M.Cap ( in Cr)7492.69
Fine Organic Inds. (BSE) 4408.05 (1.29%)	M.Cap ( in Cr)13515.07

Shareholding Pattern

	PROMOTERS	55.78%
	NON-INSTITUTION	44.19%
	MUTUAL FUNDS/UTI	0%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
No Data Found

Risk Disclosures on Derivatives

Smart Quotes

TITAN BIO-TECH LTD.